Cancer researchers have demonstrated a method to reprogram tumour cells into benign cells in what could be a dramatic breakthrough in the fight against the disease.
Scientists warn the method has only been trialled ‘in vitro’, and has not been tested on live human patients. But the hope is the technique may lead to a treatment for different cancers far less destructive than chemotherapy.
Cancer cells are essentially the same as normal cells, but instead of stopping the process of division during replication, they continue to divide. The result is a tumour. The instruction to stop dividing is usually controlled by microRNAs, small but critical biological markers within the cells, but something happens inside cancerous cells which stops that process.
The team at the Mayo Clinic in Florida found that by injecting human breast and bladder cancer cells with PLEKHA7 — the protein thought to stop cells dividing when added in the right quantities — they could transform cancer cells into benign cells. The insight into the role of PLEKHA7 helped the team understand how the behaviour of proteins E-cadherin and p120 catenin, which are critical for holding normal tissue together while also powering cancer division, could be regulated.
“We should be able to re-establish the brakes and restore normal cell function,” professor Panos Anastasiadis, of the Department for Cancer Biology at Mayo told The Telegraph. “Initial experiments in some aggressive types of cancer are indeed very promising.”
The study, published in Nature Cell Biology, is in theory a dramatic discovery, and if applicable in human trials would give doctors the ability to tell tumours to stop growing entirely.
“The study brings together two so-far unrelated research fields — cell-to-cell adhesion and miRNA biology — to resolve a long-standing problem about the role of adhesion proteins in cell behavior that was baffling scientists,” lead author Antonis Kourtidis said in a press statement “Most significantly, it uncovers a new strategy for cancer therapy.”
The Latest on: Reprogram tumour cells
via Google News
The Latest on: Reprogram tumour cells
- Ted Kennedy’s brain cancer on May 20, 2019 at 4:28 am
The small interfering RNA are balls of RNA structured in a unique, ball shape that contains gold, which allows the interfering RNA to get into the neurons to reprogram the cancer cells so they can ... […]
- miR-23b-3p suppressing PGC1α promotes proliferation through reprogramming metabolism in osteosarcoma on May 16, 2019 at 4:18 am
2: miR-23b-3p inhibited OXPHOS and facilitated the aerobic glycolysis in OS cells and directly targeted PGC1α. In summary, our study revealed the role and mechanism of miR-23b-3p in the OS ... […]
- Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting on May 15, 2019 at 2:16 pm
The presentation, titled "THOR-707: Using synthetic biology to reprogram the therapeutic activity of interleukin ... 707 + anti-PD-1 were found to reject additional challenges with tumor cells without ... […]
- New strategy of reprogramming regulatory T cells may improve cancer therapies on May 15, 2019 at 10:03 am
"Many patients' tumors do not respond to immune therapies ... are reprogrammed through targeting of the CBM complex. The ability to reprogram Treg cells to improve patient response to immune ... […]
- Cancer hurts like hell but breathing (yes breathing) is helping me cope on May 10, 2019 at 9:38 am
I decided to take myself off to reset, to give myself a chance to take some time out to reflect. I did some exercise - and amazed myself at what a cancer-battered body can do. But the thing that most ... […]
- Cancer cure? Why scientist believed ‘anti-ageing plant’ could also be ‘MIRACLE fix’ on May 8, 2019 at 5:33 am
“We use it to reset ageing within cells – it is very important in controlling both ageings and cancer. “We want to be able to turn it on so we can prevent ageing and cure age-related diseases. “We ... […]
- Jounce Therapeutics Reports First Quarter 2019 Financial Results on May 8, 2019 at 3:30 am
The characteristics of ICOS hi CD4 T cells associated with vopratelimab ... and is believed to reprogram tumor-associated macrophages within the tumor microenvironment. Highlights from the poster ... […]
- TCR2 Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity of the Company’s Novel TRuC™-T Cells on May 7, 2019 at 3:00 am
The findings suggest profound differences in signaling between TRuC-T and CAR-T cells. "We report that fusion of an antibody-based binding domain to TCR subunits can effectively reprogram an intact ... […]
- Hebrew University researchers create embryo stem cells from skin cells on May 1, 2019 at 4:11 pm
“You could say we are close to generating a synthetic embryo, which is a really crazy thing,” said Dr. Yossi Buganim of the university’s Department of Developmental Biology and Cancer ... into skin ... […]
- Cancer drugs reprogram genes in breast tumors to prevent endocrine resistance, finds study on April 24, 2019 at 12:15 am
The two drugs used in the study, selinexor and 4-OHT, caused the cancer cells to die and tumors to regress for prolonged periods, said food science and human nutrition professor Zeynep Madak-Erdogan, ... […]
via Bing News